Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. (17th April 2018)

• Record Type: Journal Article
• Authors: Sun, Shangjun; Hao, He; Yang, Ge; Zhang, Yi; Fu, Yang
• Other Names: Holland Martin Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2018(2018)
• Publication Date: 2018-04-17
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2018/2386187
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has also highlighted its potential treatment-related toxicities. The adverse events observed in the clinical trials are described in this review, after which, some innovative strategies developed to overcome these unwanted toxicities are outlined, including suicide genes, targeted activation, and other novel strategies.